Castle Creek Biosciences, Inc.

[Not Yet Scheduled]
Castle Creek Biosciences, Inc. is a late-clinical stage cell and gene therapy company focused on developing and planning to commercialize disease-modifying and potentially curative therapies for patients living with rare genetic diseases. Castle Creek’s most advanced product candidate, dabocemagene autoficel (FCX-007, D-Fi), an ex vivo, autologous gene therapy, is currently being evaluated in a Phase 3 clinical trial for the localized treatment of chronic wounds due to recessive dystrophic epidermolysis bullosa (RDEB). In addition, LV-FAH, an in vivo, investigational gene therapy candidate, is being assessed in preclinical studies for the treatment of hereditary tyrosinemia type 1 (HT1). The company is pursuing discovery and development of early-stage novel product candidates utilizing its dual platform of ex vivo and in vivo technologies to expand its robust pipeline. Castle Creek Biosciences, Inc. is a portfolio company of Paragon Biosciences, LLC.
Company Type:
Privately Funded Company
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
D-Fi gene therapy for treatment of recessive dystrophic epidermolysis bullosa (RDEB)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
PRESIDENT AND CEO
Castle Creek Biosciences